Presentations by Program

In Vitro Activity of Sulbactam-Durlobactam against Recent Clinical Acinetobacter baumannii-calcoaceticus Complex Isolates

Sarah McLeod, Samir Moussa, Meredith Hackel and Alita Miller

Sulbactam-Durlobactam MIC and Disk Diffusion Quality Control Ranges Using A CLSI M23-A4 Study Design

Sarah McLeod, Nicole Carter and Alita Miller

Effect Of Susceptibility Testing Conditions On The In Vitro Antibacterial Activity Of Sulbactam-Durlobactam

Nicole Carter, Sarah McLeod and Alita Miller

Outer Membrane Permeability and Efflux Do Not Limit Antibacterial Activity of Sulbactam-Durlobactamin Acinetobacter baumannii

Nicole M. Carter, Samir H. Moussa, Sarah M. McLeod, Alita A. Miller and Ramkumar Iyer

Serious Infections Caused by Carbapenem Susceptible and Carbapenem Resistant Acinetobacter baumannii-calcoaceticus Complex – A Retrospective Review

Rana K, Wunderink R, Tsuei B, Rahav G, Kovalchuk E, Koksal I, Maloney K and Srinivasan S (IDWeek 2020)

Sulbactam-Durlobactam (ETX2514) Is Active Against Recent, Multidrug-Resistant Acinetobacter baumannii Clinical Isolates from the Middle East

McLeod S, Moussa S, Hackel M and Miller A (IDWeek 2020)

A Novel β-lactamase Inhibitor (Durlobactam, DUR) and β-Lactams Enhance Susceptibility Against Multidrug Resistant (MDR) Mycobacterium abscessus (Mab)

Dousa KM, Kurz SG, Bethel CR, Taracilla M, Miller AA and Bonomo RA (IDWeek 2020)

In Vitro Activity of Sulbactam-Durlobactam (ETX2514) Against Recent Global Clinical Acinetobacter baumannii-calcoaceticus Complex Isolates

McLeod S, Moussa S, Hackel M and Miller A (IDWeek 2020)

In Vitro Antibacterial Activity of Sulbactam Durlobactam (ETX2514) against 121 Recent Acinetobacter baumannii Isolates from Patients in India

McLeod SM, Mathur T, Hackel M, Wise M, Morrissey I and Miller AA (IDWeek 2019)

In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam (ETX2514) against Pathogenic Burkholderia Species

Miller AA, O'Donnell JP, Lane DJ, Panchal RG and Mueller JP (IDWeek 2019)